3 recruiting, 1 active not recruiting, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow sodium-iodide symporter: new trials by email Literature Review of sodium-iodide symporter trials Research Report on sodium-iodide symporter
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
| VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate - Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma | Phase 1 | Active not recruiting | Mayo Clinic | 34 | 2017-09-15 | 2026-07-21 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria NIS (Non Interventional Study) observational study - Oncology, Epidemiology | Completed | AstraZeneca | 1500 | 2016-05-29 | 2023-04-03 |
Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Mycosis Fungoides (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Endometrial Neoplasms (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1)
Mayo Clinic (4) · AstraZeneca (1)
United States (4) · Algeria (1)
Ahmed Bendib, Oncologist (1) · Brian A. Costello, MD (1) · Jamie N. Bakkum-Gamez, M.D. (1) · Joselle Cook, M.B.B.S. (1) · Kah Whye Peng, PhD (1) · Nora Bennani, M.D. (1) · Nora Bennani, MD (1)
P50CA186781 (2), R01CA262613 (2), R01CA207240 (1)